GRI:NSD-GRI Bio Inc. (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 1.43

Change

-0.02 (-1.38)%

Market Cap

N/A

Volume

0.06M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-2.03 (-0.46%)

USD 128.84B
REGN Regeneron Pharmaceuticals Inc

-1.86 (-0.38%)

USD 65.38B
ARGX argenx NV ADR

+7.09 (+1.24%)

USD 34.54B
ALNY Alnylam Pharmaceuticals Inc

+2.69 (+0.88%)

USD 32.75B
ONC BeiGene, Ltd.

-1.27 (-0.49%)

USD 27.70B
RPRX Royalty Pharma Plc

+0.31 (+0.93%)

USD 18.35B
SMMT Summit Therapeutics PLC

+0.17 (+0.87%)

USD 13.53B
INSM Insmed Inc

-0.95 (-1.29%)

USD 11.84B
INCY Incyte Corporation

-0.18 (-0.27%)

USD 11.42B
BMRN Biomarin Pharmaceutical Inc

-0.84 (-1.50%)

USD 11.29B

ETFs Containing GRI

UKPH:XETRA iShares UK Property UCITS.. 3.23 % 0.00 %

-0.02 (-0.40%)

N/A
IUKP:LSE iShares UK Property UCITS 3.07 % 0.00 %

-1.25 (-0.40%)

USD 0.51B
IUKP:SW iShares UK Property UCITS.. 3.03 % 0.00 %

N/A

USD 0.51B
UKRE:LSE iShares MSCI Target UK Re.. 0.00 % 0.00 %

-2.20 (-0.40%)

USD 0.10B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -89.85% 2% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.85% 2% F 1% F
Trailing 12 Months  
Capital Gain -97.70% 3% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -97.70% 3% F 2% F
Trailing 5 Years  
Capital Gain -100.00% N/A F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -100.00% N/A F N/A F
Average Annual (5 Year Horizon)  
Capital Gain -45.26% 4% F 2% F
Dividend Return -45.26% 4% F 2% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.42% 64% D 37% F
Risk Adjusted Return -93.47% 10% F 5% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector